Información del artículo
La Asociación Española de Pediatría creó en 1994 el Comité Asesor de Vacunas con el fin de asesorar a los pediatras en temas vacunales y realizar recomendaciones de calendario vacunal. Las últimas recomendaciones son parael período 2001–2002, en las que lo más significativo es laindicación de la vacunación con vacuna antipoliomielíticainactivada (VPI) en sustitución de la vacuna oral atenuada(VPO). Se incide nuevamente en la conveniencia de incluirla vacuna contra la varicela en los esquemas vacunales delniño sano
Palabras clave:
Calendario vacunal
Vacunación
Vacunas pediátricas
Poliomielitis
Hepatitis B
Varicela
Tos ferina
In 1994 the Spanish Association of Pediatrics foundedthe Advisory Committee on Vaccines with the aim of providing advice on matters related to childhood immunizations and of implementing vaccination schedules. Thelatest recommendations concern the immunization schedule for 2001–2002, in which indications for the inactivated poliovirus vaccine instead of the attenuated poliovirusvaccine are of prime importance. The advisability of including the vaccine against chicken pox in healthy childrenis stressed
Key words:
Immunization schedule
Vaccination
Pediatric vaccines
Poliomyelitis
Hepatitis B
Varicella
Pertussis
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Dal-Ré, J. Arístegui, A. González.
Inmunidad frente a la difteriaen adultos jóvenes en España.
Med Clin (Barc), 17 (1995), pp. 676
[2.]
I. Pachón, C. Amela, F. De Ory, P. León, M. Alonso.
Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Año 1996.
Bol Epidemiol Semanal, 6 (1998), pp. 93-104
[3.]
P. Garcia-Corbeira, R. Dal-Ré, J. García de Lomas, L. Aguilar.
Low prevalence of diphtheria immunity in the Spanish population: results of a cross-sectional study.
Vaccine, 17 (1999), pp. 1978-1982
[4.]
M. Español, C. Muñoz, G. Prats.
Inmunidad frente a la difteria de una muestra representativa de la población de Barcelona determinada mediante una técnica inmunoenzimática.
Vacunas Investigación y Práctica, 1 (2000), pp. 59-64
[5.]
J. Vidal, A. Domínguez, P. Plans, L. Salleras.
Seroepidemiología en la población adulta de Cataluña, 1989-1996.
Vacunas Investigación y Práctica, 1 (2000), pp. 153-156
[6.]
S. Dittmann.
Strategy for pertussis prevention in the World Health Organization’s European Region.
J Infect Dis, 174 (1996), pp. S291-S294
[7.]
Q. He, J. Mertsola.
Epidemiology and prevention of pertussis.
Curr Opin Pediatr, 9 (1997), pp. 14-18
[8.]
J.M. Eiros Bouza, R. Ortiz de Lejarazu, A. Orduña Domingo, M.R. Bachiller Luque.
Estudio seroepidemiológico en niños vacunados frente a tos ferina.
An Esp Pediatr, 41 (1994), pp. 285-286
[9.]
Informe: II Encuesta de seroprevalencia. Tos ferina.
Bol Epidemiol Comunidad de Madrid, 4 (1995), pp. 13-14
[11.]
M.E. Nennig, H.R. Shinefield, K.M. Edwards, S.B. Black, B.H. Fireman.
Prevalence and incidence of adult pertussis in an urban population.
Jama, 275 (1996), pp. 1672-1674
[13.]
P. García-Corbeira, R. Dal-Ré, L. Aguilar, J. García-de-Lomas.
Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study.
Vaccine, 18 (2000), pp. 2173-2176
[14.]
American Academy of Pediatrics. Committee on Infectious Diseases: Prevention of poliomyelitis: recommendations for the use of only inactivated poliovirus vaccine for routine immunization.
Pediatrics, 104 (1999), pp. 1404-1406
[15.]
Centers for Disease Control and Prevention. Progress toward global poliomyelitis eradication, 1999.
MMWR, 49 (2000), pp. 349-354
[16.]
EUR/ICP/CMDS 03 01 13. Poliomyelitis eradication. Report onthe firts meeting of the Europen Regional Commission for thecertification of poliomyelitis eradication. París, 1996
[17.]
T.J. John.
The final stages of the global eradication of polio.
N Engl J Med, 343 (2000), pp. 806-807
[18.]
L. Salleras, A. Domínguez.
Prospects for global poliomyelitis eradication. Vacunas.
Investigación y Práctica, 1 (2000), pp. 178-187
[19.]
Organización Mundial de la Salud, (1988),
[20.]
H. Faden, L. Duffy, M. Sun, C. Shuff.
Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccine.
J Infect Dis, 168 (1993), pp. 452-454
[21.]
R.W. Sutter, A.J. Suleiman, P. Malankar, S. Al-Khusaiby, F. Mehta, G.B. Clements, et al.
Trial of a supplemental dose of four poliovirus vaccines.
N Engl J Med, 343 (2000), pp. 767-773
[22.]
I. Pachón, A. Pizarro.
Erradicación de la poliomielitis. Sistema de vigilancia de parálisis fláccida aguda.
Bol Epidemiol Sem, 6 (1998), pp. 221-224
[23.]
I. Pachón, M.C. Sanz.
Certificación de la erradicación de la poliomielitis. Sistema de Vigilancia de Parálisis Flácida Aguda.
Bol Epidemiol Semanal, 7 (1999), pp. 189-192
[24.]
Centers for Disease Control and Prevention. Circulation of a type 2 vaccine-derived poliovirus - Egypt, 1982-1993.
MMWR, 50 (2001), pp. 41-42
[25.]
Centers for Disease Control and Prevention. Outbreak of poliomyelitis-Dominican Republic and Haiti, 2000.
MMWR, 49 (2000), pp. 1094-1103
[26.]
Dirección General de Salud Pública. Ministerio de Sanidad y Consumo. Programas de vacunación frente a la hepatitis B en adolescentes. Periodo 1996-1997.
Bol Epidemiol Semanal, 6 (1998), pp. 209-210
[27.]
H. Peltola, P. Aavitsland, K.G. Hansen, K.E. Jonsdottir, H. Nokleby, V. Romanus.
Perspective: a five-country analysis of the impact of four differentHaemophilus influenzaetype b conjugates and vaccination strategies in Scandinavia.
J Infect Dis, 179 (1999), pp. 223-229
[28.]
H. Peltola.
Haemophilus influenzaetype b disease and vaccination in Europe: lessons learned.
Pediatr Infect Dis J, 17 (1998), pp. S126-S132
[29.]
J.C. Watson, J.A. Pearson, L.E. Markowitz, A.L. Baughman, D.D. Erdman, W.J. Bellini, et al.
An evaluation of measles revaccination among school-entry-aged children.
Pediatrics, 97 (1996), pp. 613-618
[30.]
American Academy of Pediatrics. Committe on Infectious Diseases.Age for Routine Administration of the second dose of measles-mumps-rubella vaccine.
Pediatrics, 101 (1998), pp. 129-133
[31.]
S. Lockhart.
Meningococcal serogroup C conjugate vaccines. A clinical review. Vacunas.
Investigación y Práctica, 1 (2000), pp. 126-129
[32.]
J.M. MacLennan, F. Shackley, P.T. Health, J.J. Deeks, C. Flamank, M. Herbert.
Safety, immunogenicity and induction of immnunologic memory by a serogroup C conjugate vaccine in infants.
Jama, 283 (2000), pp. 2795-2801
[33.]
M.B. Rennels, K.M. Edwards, H.L. Keyserling, K.S. Reisinger, MM. Blatter, A. Sally.
Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197in United States infants.
Pediatr Infect Dis J, 20 (2001), pp. 153-159
[34.]
P. Richmond, R. Borrow, E. Miller, S. Clark, F. Sadler, A. Fox.
Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.
J Infect Dis, 179 (1999), pp. 1569-1572
[35.]
M. Ramsay, N. Andrews, E.B. Kaczmarski, E. Miller.
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.
Lancet, 357 (2001), pp. 195-196
[36.]
S. Mateo, R. Cano, C. García.
Changing epidemiology of meningococcal disease in Spain, 1989-1997.
Eurosurveillance, 2 (1997), pp. 71-74
[37.]
L. Salleras, A. Domínguez, J. Vidal, P. Plans, M. Salleras, J.L. Taberner.
Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes.
Vaccine, 19 (2001), pp. 183-188
[38.]
A. Jaeggi, R.P. Zurbruegg, C. Aebi.
Complications of varicella in a defined central european population.
Arch Dis Chil, 79 (1998), pp. 472-477
[39.]
F.A. Moraga, A. Dominguez, J. Roca, M. Jané, N. Torner, L. Salleras.
and the Group for the study of varicella complications in Catalonia. Paediatric complications of varicella requiring hospitalisations.
Vacunas, 1 (2000), pp. 106-111
[40.]
Centers for Disease Control. Varicella-related deaths among adults, United States, 1997.
MMWR, 46 (1997), pp. 409-412
[41.]
Centers for Disease Control. Varicella-related deaths among children, United States, 1997.
MMWR, 47 (1997), pp. 365-368
[42.]
American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine Update.
Pediatrics, 105 (2000), pp. 136-141
[43.]
A.M. Arbeter.
Clinical trials of varicella vaccine in healthy adolescents and adults.
Infect Dis Clin North Am, 10 (1996), pp. 609-615
[44.]
P.R. Krause, D.M. Klinman.
Varicella Vaccination: evidence for frequent reactivation of the vaccine strain in healthy children.
Nature Med, (2000), pp. 451-454
[45.]
A.L. Pastuszak, M. Levy, B. Schick, C. Zuber, M. Feldkamp, J. Gladstone.
Outcome after maternal varicella infection in the firts 20 weeks of pregnancy.
N Engl J Med, 330 (1994), pp. 901-905
[46.]
P. Beutels, R. Clara, G. Tormans, E. Van Doorslaer.
Cots and benefits of routine varicella vaccination in german children.
J Infect Dis, 174 (1996), pp. S335-S441
[47.]
R. Diez Domingo, M. Ridao, J. Latour, A. Ballester, A. Morant.
A cost benefit analysis of routine varicella vaccination in Spain.
Vaccine, 17 (1999), pp. 1306-1311
[48.]
P. Fornaro, F. Gandini, M. Marin, C. Pedrazzi, P. Piccoli, D. Tognetti.
Epidemiology and cost análisis of varicella in Italy: results of a sentinel study in the pediatric practice.
Pediatr Infect Dis J, 18 (1999), pp. 414-419
[49.]
D.M. Huse, C. Meissner, M.J. Lacey, G. Oster.
Childhood vaccination against chickenpox: An analysis of benefits and costs.
J Pediatr, 124 (1994), pp. 869-874
[50.]
B. Law, C. Fitzsimon, L. Ford-Jones, N. MacDonald, P. Dery, W. Vaudry.
Cost of Chickenpox in Canada: Part I. Cost of uncomplicated cases.
Pediatrics, 104 (1994), pp. 1-6
[51.]
B Law, C Fitzsimon, L Ford-Jones, J McCormick, M Riviere.
Cost of chickenpox in Canada: Part II. Cost of complicated cases and total economic impact.
Pediatrics, 104 (1999), pp. 7-14
[52.]
T.A Lieu, S.L Cochi, S.B Black, M.E Halloran, H.R Shinefield, S.J Holmes.
Cost-effectiveness of a routine varicella vaccination program for US children.
Jama, 271 (1994), pp. 375-381
[53.]
J Diez Domingo.
4th Meeting.European Working Group on Varicella Vaccination, (2001),
[54.]
M Bruguera, L.I Salleras, P Plans, J Vidal, E Navas, A Domínguez.
Cambios en la seroepidemiología de la infección por el virus de la hepatitis A en Cataluña en el período 1989-1996.Implicaciones para una nueva estrategia vacunal.
Med Clin(Barc), 112 (1999), pp. 406-408
[55.]
J Arístegui, J.L Morales, R Dal-Re, A Gonzalez, M.S Gallego, E Garrote.
Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old.
Infection, 23 (1995), pp. 334-338
[56.]
M Bruguera, M Buti, M Diago, M Garcia Bengoechea, P Jara, J.D Pedreira.
Indicaciones y prescripción de la vacuna de la hepatitis A en España. Informe de la Asociación Española para el Estudio del Hígado.
Med Clin (Barc), 111 (1998), pp. 341-346
[57.]
F.A Moraga Llop.
Prous Science, (2001),
[58.]
T Nieminen, H Käyhty, O Leroy, J Eskola.
Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies.
Pediatr Infect Dis J, 18 (1999), pp. 764-772
[59.]
W.P Hausdorff, J Bryant, C Kloek, P Paradiso, G.R Siber.
Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, Part I.
Clin Infect Dis, 30 (2000), pp. 100-121
[60.]
S Black, H Shinefield, B Fireman, E Lewis, P Ray, J.R Hansen.
Safety, immunogenicity and efficacy of heptavalent pneumococcal conjugate in infancy.
Pediatr Infect Dis J, 19 (2000), pp. 187-195
[61.]
J Eskola, T Kilpi, A Palmu, J Jokinen, M Eerola, J Haapakoski.
Efficacy of a pneumococcal conjugate vaccine against acute otitis media.
N Engl J Med, 344 (2001), pp. 403-409
[62.]
H.R Shinefield, S Black, P Ray, I.H Chang, N Lewis, B Fireman.
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Pediatr Infect Dis J, 18 (1999), pp. 757-763
[63.]
A Fenoll, I Jado, D Vicioso, A Pérez, J Casal.
Evolution ofStreptococcus pneumoniae serotypes and antibiotic resistance in Spain: Update (1990 to 1996).
J Clin Microbiol, 36 (1998), pp. 3447-3454
[64.]
A Fenoll, I Jado, D Vicioso, S Berrón, J.E Yuste, J Casal.
Streptococcus pneumoniaein children in Spain: 1990-1999.
Acta Pediatr, S435 (2000), pp. 44-50
Coordinador: J. de Arístegui Fernández (pediatra).Vocales:J. Ruiz Contreras (pediatra), J.M. Corretger Rauet (pediatra), F. García Martín (pediatra), T. Hernández Sampelayo (pediatra), F. Moraga Llop (pediatra) y C. Rodrigo Gonzalo de Liria (pediatra).Asesores:F. Calbo Torrecillas (microbiólogo-preventivista), G. Fontán Casariego (inmunólogo) y J. Muñiz Saitua (epidemiólogo)
Copyright © 2001. Asociación Española de Pediatría
